When is NAGE's next earnings date?

Based on SEC filing cadence, Niagen Bioscience Inc. (NAGE)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is NAGE stock expected to move on earnings?

Volatility modeling currently projects a ±7.7% event move for NAGE, spanning a range between $2.22 and $2.58.

Stock Ratings / Health Care / NAGE / earnings

GLAS (18) MDWD (48) ACB (54) USNA (50) ⌘ Pro Terminal →

Niagen Bioscience Inc. (NAGE) Next Earnings Date & Expected ±7.7% Move

$2.40 +3.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.41

Niagen Bioscience Inc. (NAGE) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $184.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NAGE Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NAGE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Niagen Bioscience Inc. (NASDAQ: NAGE) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $2.40 (+3.00% 1D, market cap $184.4M). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 18/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NAGE compare to GLAS and MDWD in the Health Care sector?

▼

Within the Health Care sector (Medicinal Chemicals and Botanical Products), NAGE carries a Roarable D+ (57/100 RQD), trailing P/E of 11.4x, gross margin of 64.3%, and ROIC of 16.8%. By comparison, GLAS (Glass House Brands Inc. Subordinate Voting Shares) holds a E grade (18/100 RQD, P/E N/A, ROIC -9.2%, cap $191.8M) and MDWD (MediWound Ltd.) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $171.7M). Among the 5-stock peer group, NAGE leads on earnings multiple (11.4x) while NAGE leads on capital efficiency (16.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NAGE?

▼

Per NAGE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001386570), Niagen Bioscience Inc. generated $129.4M in revenue (+29.9% YoY), $17.4M in net income, and $13.5M in free cash flow against $106.4M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.41 (+0.35%)🧬 Cannibal Buyback (-2.92% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 10.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY • 52.2% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-0.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NAGE)Realized 20D OHLCV Swing Band: ±7.7%

Deterministic 5-Pillar Attribution (57/100 Composite)

🔍 WHY NAGE SCORES 57/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+18/20 pts (32% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-2.92% YoY Shares)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (25% of score)

Altman Z-Score 4.40 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$2.58-2.7% Next Q

Q2 (-2Q)

Grade C+$2.51-0.4% Next Q

Q3 (-1Q)

Grade C$2.50-4% Next Q

Current

Grade D+$2.40-0.2% Hist 90D α

Trajectory: C+ (65) → D+ (57)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the NAGE Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 57/100 (D+) score, NAGE faces multiple-compression risk if 11.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.92% YoY Shares) — any gross margin slip below 61.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($2.83) or 200D SMA ($3.88) invalidates the momentum regime and cuts Target Base ($2.39) toward Bear Floor ($1.86).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NAGE• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NAGE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 57%NO 43%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±7.7% Swing Band

±$0.18 Expected Swing

MODEL EARNINGS SETUP GAUGE

NAGE Quantitative Pre-Earnings Setup: 57/100

Trailing EPS: $0.22 • YoY Revenue Growth: 29.9%

Model Bullish Setup (57/100)Model Risk Weight (43/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$129.4M	$17.4M	$13.5M	64.3%
FY 2024	2024-12-31	$99.6M	$8.6M	$12.1M	61.8%
FY 2023	2023-12-31	$83.6M	-$4.9M	$7.1M	64.3%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NAGE)

✓Walkthrough of NAGE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NAGE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -51.32%🛡️ HOLDING TREND SUPPORT

2026-11-03O $2.50H $2.50L $2.33C $2.40VOL 526.4K

RES: $2.67SUP: $2.30SMA50: $2.83SMA200: $3.88

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NAGE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NAGE Butterfly Map → + Track NAGE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

1.5%/yr Implied 5Y Growth

vs. +29.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NAGE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NAGE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NAGE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NAGE)

Health Care Rank #194 of 1016 ⚔️ GLAS vs NAGE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NAGE vs. GLAS, MDWD, ACB, USNA)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Niagen Bioscience Inc. (NAGE) ranks #194 by composite RQD confidence (57/100, grade D+) and #587 by equity capitalization ($184.4M). Within this direct 5-issuer industry benchmark cohort, NAGE leads on earnings valuation at 11.4x trailing P/E, while NAGE leads on capital efficiency and profitability with 16.8% ROIC and 64.3% gross margin. NAGE currently leads its immediate peer cohort in composite quantitative strength at 57/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NAGE ACTIVE Niagen Bioscience Inc.	D+	57/100	11.4x	64.3%	16.8%	+3.00%	$184.4M	Benchmark Subject
GLAS Glass House Brands Inc. Subordinate Voting Shares	E	18/100	—	42.3%	-9.2%	+8.26%	$191.8M	/glas-vs-nage →
MDWD MediWound Ltd.	D	48/100	—	—	—	+1.50%	$171.7M	/mdwd-vs-nage →
ACB Aurora Cannabis Inc.	D+	54/100	—	—	—	+3.94%	$251.5M	/acb-vs-nage →
USNA USANA Health Sciences Inc.	D	50/100	24.6x	78.3%	7.9%	+2.87%	$264.4M	/usna-vs-nage →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001386570

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Niagen Bioscience Inc. (NAGE) reported GAAP revenue of $129.4M (+29.9% vs. FY2024 revenue of $99.6M , and +54.9% cumulative change since FY2023) , GAAP net income of $17.4M, operating cash flow of $13.5M, and free cash flow of $13.5M (+11.5% YoY). On the balance sheet, NAGE closed FY2025 with $106.4M in total assets against $0 in total debt (Altman Z-Score: 4.40, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$129.4M	$17.4M	$13.5M	$13.5M	$106.4M	—
FY2024 (FY)	2024-12-31	$99.6M	$8.6M	$12.1M	$12.1M	$68.3M	—
FY2023 (FY)	2023-12-31	$83.6M	-$4.9M	$7.1M	$7.1M	—	—

3. NAGE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NAGE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NAGE compare to GLAS and MDWD in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NAGE?

Where is NAGE trading relative to its 50-day, 200-day, and 52-week technical levels?

NAGE last traded at $2.40 (+3.00% on volume of 557,601 shares), positioning the stock -15.19% below its 50-day simple moving average ($2.83) and -38.14% below its 200-day simple moving average ($3.88). Across its 52-week range of $2.32 to $7.95, NAGE sits at the 1.4% percentile with a 14-day RSI of 35.9 (NEUTRAL RANGE) and an implied next-earnings move of ±7.7% ($2.22 to $2.58).

Direct Sub-Reports: NAGE RQD Cockpit NAGE 12M Forecast NAGE Earnings & Move NAGE Dividends & DRIP NAGE Insiders & 13F NAGE Whale Options NAGE Profit Sankey NAGE News & Why

ROARABLE RATING BRIEF • RQD 57/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

NAGE — Niagen Bioscience Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:41:18Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

NAGE scores 57 out of 100, a letter grade of D+, with the verdict label "Roarable Sell — Weak Fundamentals / Trim." The five pillars are: Fundamental Cash Engine at 13/20 (ROIC 16.8%; FCF yield 6.83%), Whale 13F Flow at 3/20 (institutional accumulation and options positioning), Insider Conviction at 18/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 9/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 14/20 (Altman Z 4.4; Piotroski F 7/9; Debt/Equity 0.5).

For a prospective investor, the profile is uneven. The strongest pillar is insider conviction (18/20), which per the rating reflects cluster flow in SEC Form 4 and Congressional PTR data. The weakest pillar is institutional flow (3/20), indicating limited 13F accumulation and options positioning support. The cash engine and balance sheet pillars are moderate, while macro regime fit is below midpoint given the 1.0 beta and the liquidity-sensitivity signal in the Butterfly graph. Upside drivers cited in the data include the insider cluster flow and the cash-generation metrics; the valuation tradeoff is that the stock trades at a trailing P/E of 11.4 and forward P/E of 9.6 against a 52-week range of $2.32 - $7.95 and a current price of $2.5, which the rating does not translate into a fair-value view. The rating verdict reflects an overall "Trim" stance on weak aggregate fundamentals rather than a directional price forecast.

2. Business Model, Unit Margins & SEC Financial Trajectory

Niagen Bioscience Inc. (NAGE) is a NASDAQ-listed issuer in the Health Care sector, within the Medicinal Chemicals and Botanical Products industry..2B. Customer base, product line, and revenue model details are —

Revenue rose from $83.6M (FY 2023) to $129.4M (FY 2025), and net income moved from -$4.9M to $17.4M over the same span. Per the market data, gross margin is 64.3%, operating margin 12.6%, and net margin 13.4%, with ROIC of 16.8%. 's forensic pillar, the Altman Z-Score is 4.4, the Piotroski F-Score is 7/9, and Debt/Equity is 0.5. Detailed balance sheet line items for FY 2025 and FY 2023 (cash, debt) are —

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: Insider cluster flow scores 18/20 and FY 2025 net income reached $17.4M on $129.4M revenue, with a 16.8% ROIC. With Fundamental Cash Engine at 13/20 (ROIC 16.8%, FCF yield 6.83%) and Institutional Whale Flow at 3/20, sustained execution supports upside toward the top of the $2.32 – $7.95 52-week range.
🐻 Primary Bear Case: Institutional 13F flow scores only 3/20, and the Butterfly liquidity signal rates NAGE's 2.64x net-liquidity beta as bearish with a 25/100 macro tailwind score. Investors must weigh 11.4x trailing P/E and 12.2x EV/EBITDA against 12.6% operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

A second-order watch item is that a tightening in the liquidity index would, per the signal's framing, weigh more heavily on NAGE than on the broader market. Sector correlations beyond this are —

Key Question #1: What is the consensus analyst rating and price-target distribution beyond the single referenced Canaccord Genuity target?
Key Question #2: What are FY 2025 cash, debt, and EPS figures, which are listed as N/A in the financial table?
Key Question #3: What customer concentration, product, and revenue-mix details drive the FY 2024 to FY 2025 revenue step-up?

NAGE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Niagen Bioscience Inc. (NAGE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NAGE Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 20h ago

Earnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to Decline

Yahoo Finance report covering Niagen Bioscience Inc. (NAGE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 23h ago

Niagen Bioscience, Inc. Estimates – NASDAQ:NAGE

TradingView report covering Niagen Bioscience Inc. (NAGE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

Canaccord reiterates Niagen stock rating on healthy aging strategy

Investing.com report covering Niagen Bioscience Inc. (NAGE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GuruFocus • 1d ago

Niagen Bioscience (NAGE) Launches Clinician-Directed At-Home Inj

GuruFocus report covering Niagen Bioscience Inc. (NAGE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Business Wire • 1d ago

Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

Business Wire report covering Niagen Bioscience Inc. (NAGE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Niagen Bioscience (NASDAQ:NAGE) Given New $9.00 Price Target at Canaccord Genuity Group

MarketBeat report covering Niagen Bioscience Inc. (NAGE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

ChromaDex Corp (OCD1.DU) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Niagen Bioscience Inc. (NAGE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Business Wire • 1d ago

Niagen Bioscience to Present at LD Micro 20th Annual Main Event

Business Wire report covering Niagen Bioscience Inc. (NAGE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NAGE Bull vs. Bear Conversation Board — What's Your Call at $2.40?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NAGE 🐻 33% BEARISH CONVICTION

MA MacroHawk_NYC Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $2.68 (+15.0%)

📌 Pinned Debate

Insider cluster flow scores 18/20 and FY 2025 net income reached $17.4M on $129.4M revenue, with a 16.8% ROIC.

Insider cluster flow scores 18/20 and FY 2025 net income reached $17.4M on $129.4M revenue, with a 16.8% ROIC.. When you look under the hood at NAGE, Fundamental Cash Engine is 13/20 with 64.3% gross margins and 16.8% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $7.95. My 12M target is $2.68.

VolSurface_Trader 🐂 BULL

Both sides have a point here — NAGE's 14/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA Fundamental Contrarian 🐻 BEARISH 🎯 Target: $1.89 (-18.9%)

Spot @ $2.33

Institutional 13F flow scores only 3/20, and the Butterfly liquidity signal rates NAGE's 2.64x net-liquidity beta as bearish with a 25/

Careful chasing NAGE at $2.33. Institutional 13F flow scores only 3/20, and the Butterfly liquidity signal rates NAGE's 2.64x net-liquidity beta as bearish with a 25/100 macro tailwind score.. Gross margin is 64.3%, but operating margin is 12.6%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.89 on multiple compression.